163 related articles for article (PubMed ID: 15488654)
21. Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors.
Cherlet T; Murphy LC
Mol Cell Biochem; 2007 Dec; 306(1-2):33-42. PubMed ID: 17660955
[TBL] [Abstract][Full Text] [Related]
22. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
23. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.
Vasanwala FH; Kusam S; Toney LM; Dent AL
J Immunol; 2002 Aug; 169(4):1922-9. PubMed ID: 12165517
[TBL] [Abstract][Full Text] [Related]
24. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.
Malorni L; Giuliano M; Migliaccio I; Wang T; Creighton CJ; Lupien M; Fu X; Hilsenbeck SG; Healy N; De Angelis C; Mazumdar A; Trivedi MV; Massarweh S; Gutierrez C; De Placido S; Jeselsohn R; Brown M; Brown PH; Osborne CK; Schiff R
Mol Cancer Res; 2016 May; 14(5):470-81. PubMed ID: 26965145
[TBL] [Abstract][Full Text] [Related]
25. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway.
Sauvé K; Lepage J; Sanchez M; Heveker N; Tremblay A
Cancer Res; 2009 Jul; 69(14):5793-800. PubMed ID: 19584281
[TBL] [Abstract][Full Text] [Related]
26. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
Liu Y; Ludes-Meyers J; Zhang Y; Munoz-Medellin D; Kim HT; Lu C; Ge G; Schiff R; Hilsenbeck SG; Osborne CK; Brown PH
Oncogene; 2002 Oct; 21(50):7680-9. PubMed ID: 12400010
[TBL] [Abstract][Full Text] [Related]
28. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
29. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Ramaswamy B; Majumder S; Roy S; Ghoshal K; Kutay H; Datta J; Younes M; Shapiro CL; Motiwala T; Jacob ST
Mol Endocrinol; 2009 Feb; 23(2):176-87. PubMed ID: 19095770
[TBL] [Abstract][Full Text] [Related]
30. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
[TBL] [Abstract][Full Text] [Related]
31. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
Kang J; Qian PX; Pandey V; Perry JK; Miller LD; Liu ET; Zhu T; Liu DX; Lobie PE
Oncogene; 2010 Jun; 29(22):3228-40. PubMed ID: 20305694
[TBL] [Abstract][Full Text] [Related]
32. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.
Madeo A; Vinciguerra M; Lappano R; Galgani M; Gasperi-Campani A; Maggiolini M; Musti AM
Oncogene; 2010 Feb; 29(7):978-91. PubMed ID: 19935718
[TBL] [Abstract][Full Text] [Related]
33. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells.
Zhao B; Yu W; Qian M; Simmons-Menchaca M; Brown P; Birrer MJ; Sanders BG; Kline K
Mol Carcinog; 1997 Jul; 19(3):180-90. PubMed ID: 9254885
[TBL] [Abstract][Full Text] [Related]
34. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
35. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
36. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
38. Autocrine interferon-γ may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor β subtype.
Niu XL; Wang Y; Yao Z; Duan H; Li Z; Liu W; Zhang H; Deng WM
Oncol Rep; 2015 Dec; 34(6):3120-30. PubMed ID: 26397740
[TBL] [Abstract][Full Text] [Related]
39. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
40. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
